Related Experiment Videos
[Long-term therapy in ulcerative colitis and Crohn's disease]
Fortschritte Der Medizin
|August 2, 1979
Summary
Long-term sulphasalazine treatment can extend remission in ulcerative colitis patients. Surgery is recommended if medical therapy fails, to prevent drug side effects and cancer risk.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Context:
- Ulcerative colitis (UC) management presents challenges in maintaining long-term remission.
- Identifying optimal therapeutic strategies for UC is crucial for patient outcomes.
Purpose:
- To evaluate the efficacy of long-term sulphasalazine therapy in extending remission periods for ulcerative colitis patients.
- To establish guidelines for surgical intervention when medical management proves insufficient.
Summary:
- Long-term administration of 2-3 g of sulphasalazine daily was observed to prolong the remission phase in patients diagnosed with ulcerative colitis.
- Proctocolectomy is indicated for patients unresponsive to sustained medical treatment.
- Surgical intervention is advised to mitigate potential adverse effects associated with prolonged drug use and to reduce the elevated risk of colorectal cancer.
Impact:
- This study provides evidence supporting the role of sulphasalazine in the long-term management of ulcerative colitis.
- The findings offer guidance on the timely consideration of surgical options for refractory cases, balancing treatment benefits against risks.